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a b s t r a c t
Angiotensin converting enzyme 2 (ACE2) is a component of the renin–angiotensin system (RAS) which
converts Ang II, a potent vasoconstrictor peptide into Ang 1–7, a vasodilator peptide which may act as a
negative feedback hormone to the actions of Ang II. The discovery of this enzyme added a new level of
complexity to this system. The mesangial cells (MC) have multiple functions in glomerular physiology
and pathophysiology and are able to express all components of the RAS. Despite of being localized in
these cells, ACE2 has not yet been puriﬁed or characterized. In this study ACE2 from mice immortalized
MC (IMC) was puriﬁed by ion-exchange chromatography. The puriﬁed enzyme was identiﬁed as a single
band around60–70kDaonSDS-polyacrylamide gel andbyWesternblottingusing a speciﬁc antibody. Theenin–angiotensin system optima pH and chloride concentrationswere 7.5 and 200mM, respectively. TheN-terminal sequencewas
homologous with many species ACE2 N-terminal sequences as described in the literature. ACE2 puriﬁed
from IMC was able to hydrolyze Ang II into Ang 1–7 and the Km value for Ang II was determined to be
2.87±0.76M. In conclusion, we puriﬁed and localized, for the ﬁrst time, ACE2 in MC, which was able
to generate Ang 1–7 from Ang II. Ang 1–7 production associated to Ang II degradation by ACE2 may exert
a protective effect in the renal hemodynamic.. Introduction
Angiotensin converting enzyme 2 (ACE2) is a zinc metal-
oprotease described by two different groups in 2000 which
hares homology with angiotensin converting enzyme (ACE) in
ts catalytic domain and provides different key functions in the
enin–angiotensin system(RAS) [1,2]. In 2003 itwas shown to serve
s a receptor for the Severe Acute Respiratory Syndrome (SARS)
oronavirus [3].
ACE2 contains a single HEXXH zinc-binding motif and is able to
ydrolyze angiotensin I (Ang I) toproduce angiotensin (1–9) [1] and
lso has a greater high afﬁnity for angiotensin II (Ang II) to generate
ngiotensin (1–7) (Ang I–7) [4,5]. The speciﬁcity is not limited to
eptides belonging to the RAS and can also act on several peptides
romother systems such as neurotensin 1–13, apelin 13, dynorphin
–13 and some of the kinin metabolites, but not on bradykinin [4].
∗ Corresponding author at: Universidade Federal de São Paulo, Escola Paulista de
edicina, Departamento de Medicina, Disciplina de Nefrologia, Rua Botucatu, 740,
EP 04023-900, São Paulo, SP, Brazil. Tel.: +55 11 59041684; fax: +55 11 59041683.
E-mail address: dulce@nefro.epm.br (D.E. Casarini).
141-8130/© 2011 Elsevier B.V. Open access under the Elsevier OA license.
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This enzyme addedmore complexity to the RASwhich is known
to be involved on cardiovascular and renal homeostasis through
the control of blood pressure, body ﬂuid homeostasis and other
cardiovascular functions, counter-regulatingAng II-induced effects
[6]. Ang 1–7 may act as a negative feedback hormone to the actions
ofAng II being cardio and renoprotective [7].Most tissues, including
kidney, heart, and testis express a local RAS that acts independently
of the circulating one [1,2,6,8,9].
The mesangial cells (MC) are able to express the protein and
mRNA for all the components of the RAS, for example, renin,
angiotensinogen, ACE [10–13] and have multiple functions in the
glomerular physiology and pathophysiology. Studies in rat kidney
have shown the presence of ACE2 in renal tubules and glomeruli
[14–16], suggesting the possible existence of the enzyme in
MC.
In contrast to the growing availability of data on the enzyme
kinetics and possible physiological roles of ACE2, comparatively
little is known about ACE2 at the cellular level.
Since cultured MC provide a convenient model for the study
of renal synthesis and release of bioactive products, which could
act as autocrine, intacrine and/or paracrine mediators [17–19], this
cell line can be introduced as a suitable in vitro model in order to
improve the knowledge of events related to regulation of the renal
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CE2 levels and to further elucidate its role(s) in vivo as a target of
reatment for kidney diseases.
The aim of this study was to evaluate the existence of ACE2
n mice immortalized mesangial cells (IMC) and then, to isolate,
urify, characterize and localize this enzyme.
. Materials and methods
This studywas approved by the Ethics Committee of the Federal
niversity of São Paulo (UNIFESP), São Paulo, Brazil.
.1. Immortalized mesangial cells culture (IMC)
IMC from mice were purchased from The American Type
f Culture Collection (ATCC: CRL-1927). Cells were plated onto
MEM/F12 (3:1) (Gibco, USA) supplemented with 5% fetal bovine
erum (FBS), 5000U/L penicillin and 50mg/L streptomycin. Before
he experiments, the IMC were incubated with DEMEN/F12 with-
ut FBS for 20h [20]. The culture ﬂasks were rinsed twice with
mL of 25mM Tris–HCl buffer pH 8.0 containing 20mM pep-
tatin and 10mM PMSF, protease inhibitors, to eliminate all serum
esidues and scraped with 2mL of the same buffer at 4 ◦C. The cells
rom 40 culture plates were collected, sonicated and centrifuged at
000 rpm for 10min. The supernatant constituting the cell lysate
as dialyzed and concentrated 100 fold against 25mM Tris–HCl
uffer containing 10M ZnCl2, 20mM pepstatin and 10mM PMSF
H 8.0 at 4 ◦C using Amicon Ultra (Millipore, USA) with a 30kDa
oremembrane. The aliquotswere fractioned and stored at −20 ◦C.
.2. Puriﬁcation of ACE2 from IMC
Concentrated samples were puriﬁed on a Fast Liquid Pro-
ein Chromatography system (FPLC, AmershamPharmacia Biotech,
SA) using 1mL Resource-Q ion exchange column (Amersham
harmacia Biotech, USA) equilibrated with 25mM Tris–HCl buffer
H 8.0, containing 10M ZnCl2 (buffer A). The enzyme was eluted
ith 25mM Tris–HCl buffer pH 8.0, containing 1M NaCl, 10M
nCl2 (buffer B) using a linear gradient of 0–100%buffer B. Fractions
0.5mL)werecollectedat aﬂowrateof0.5mL/min. Theoptical den-
ity of each fractionwasquantiﬁed at 280nmandACE2activitywas
etermined using ﬂuorogenic substrate.
.3. Protein determination
Protein concentrationwas determined by BradfordMethod [21]
sing bovine albumin as standard (Bio-Rad Protein Assay Kit, Bio-
ad Laboratories, USA) except when absorbance at 280nm was
sed for the chromatographic elution proﬁle.
.4. Enzymatic activity assay
ACE2 catalytic activity was measured ﬂuorometrically using
bz-Ser-Pro-Tyr(NO2)-OH (Abz-SPY(NO2)) as substrate (Peptides
nternational, USA). An aliquot of puriﬁed enzyme was incubated
n 1mL of 100mM Tris–HCl buffer pH 7.5, containing 10M ZnCl2,
.5M captopril (ACE inhibitor), 50nM thiorphan (Neprilysin
nhibitor) and 10M of ﬂuorogenic substrate at 37 ◦C for 4h. ACE
nd Neprilysin inhibitors were used to avoid unspeciﬁc substrate
leavage in chromatographic fractions. The ﬂuorescence was mea-
uredusingF-2000Fluorescent Spectrophotometer (Hitachi, Japan)
ith an excitation of 320nm and an emission of 420nm.ogical Macromolecules 49 (2011) 79–84
2.5. Characterization of puriﬁed ACE2
2.5.1. Speciﬁcity ACE2 assay
The enzyme was pre-incubated with 1M, 10M and 100M
of DX600 (Phoenix Pharmaceutical, USA) for 30min at 37 ◦C, then
incubated with the ﬂuorogenic substrate for ACE2 as described
above.
2.5.2. pH proﬁle of puriﬁed ACE2
The activity of puriﬁed ACE2 at different pH values was
measured at 37 ◦C and incubation with Abz-SPY(NO2) as men-
tioned. The following buffers were used: 125mM sodium acetate
(4.0 >pH>5.5), 125mMsodiumphosphate (5.5 >pH>8.0), 125mM
Tris–HCl (8.0 >pH>8.5) and 125mM glycine (pH<9.0).
2.5.3. Effect of Cl− on puriﬁed ACE2 activity
The effect of Cl− on puriﬁed ACE2 was determined in 100mM
Tris–HCl buffer pH 7.5 with NaCl concentration ranging from
50mM to 1500mM. ACE2 activity was determined as mentioned
above.
2.5.4. Effect of temperature on puriﬁed ACE2 activity
In order to analyze the inﬂuence of temperature on ACE2 activ-
ity, the enzyme was pre-incubated by itself for 30min at 4 ◦C, 37 ◦C
and 56 ◦C before the addition of the buffer and the ﬂuorogenic sub-
strate. ACE2 activity was measured as mentioned above.
2.5.5. SDS-PAGE and Western blotting analysis
Proteins were analyzed by sodium duodecil sulfate-
polyacrylamide gel (7.5%) electrophoresis (SDS-PAGE) under
reducing condition [22]. Electrophoretic transfer was performed
for 1h under constant voltage (45V), using a transfer nitrocellulose
membrane (Millipore, USA) and transfer buffer (15mmol/L Tris,
190mmol/L glycine, and 0.1% SDS). The membrane was incubated
in 0.1mol/L TBS containing 3mg/mL bovine albumin for 1h before
overnight incubation with anti-ACE2 polyclonal antibody (H-175,
Santa Cruz Biotechnology, USA) (1:500 dilution). Subsequent
steps were performed using the streptavidin/phosphatase alkaline
system (Amershan Pharmacia Biosciences, USA) and the protein
bands were developed using BCIP/NBT as substrate (Bio-Rad
Laboratories, USA) as recommended by the manufacturer. Full
Range Rainbow (Amersham Biosciences, USA) was used as protein
molecular weight marker. Image analysis was performed using
GS-710 Callibrated Imaging Densitometer (Bio-Rad Laboratories,
USA).
2.5.6. Amino-terminal sequence of puriﬁed ACE2
After SDS-PAGE, proteins were electroblotted to a PVDF pro-
tein sequencing membrane (Bio-Rad Laboratories, USA) using a
100mM CAPS buffer, pH 11.0. Membrane was stained with 2%
Ponceau-S in 1% acetic acid targeting the protein localization. ACE2
bandwas excised from themembrane and submitted toN-terminal
amino acid sequencing on a PPSQ-23Automated Protein Sequencer
(Shimadzu Corporation, Japan). The sequencing was generously
performed by Dr Isaura Yoshico Hirata, from the Biophysics Divi-
sion, UNIFESP, Brazil.
2.5.7. Identiﬁcation of peptide bond in Ang II hydrolyzed by
puriﬁed ACE2
The product derived from Ang II after hydrolysis by puriﬁed
ACE2 were separated by HPLC with UV detection and compared
with standard peptides. Ang II (10nmol) was incubated for 24h
with puriﬁed enzyme in 10mM Hepes buffer, pH 7.4 containing
125mMNaCland10MZnCl2 10Mpepstatin, 20MPMSF,1M
captopril and 50nM Thiorphan. Aliquots were taken at 0 and 24h
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Fig. 1. Ion-exchange chromatography using Resource-Q column of concentrated
cell lysate from IMC. ACE2 was eluted in one peak (P1) with enzymatic activity
using Abz-SPY(NO2) as substrate. Fractions (0.5mL) were collected at a ﬂow rate of
0.5m/min with a linear gradient (0–100% NaCl 1M). ( ) OD 280nm (––) ACE2
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Fig. 2. (A) pH proﬁles of ACE. The optimal pH ACE activity was assayed using Abz-
SPY(NO2) as substrate in buffers with pH ranging from 4.0 at 9.0. (B) Effect of NaCl
on the activity ACE2. The inﬂuence of Cl− on ACE2 activity was determined using
The enzymatic activity of puriﬁed ACE2 was analyzed using thectivity (—–) % NaCl.
f incubation. The hydrolysis products were analyzed by reverse-
haseHPLCusing anAquaporeODS300 column, 7m,equilibrated
ith 0.1% phosphoric acid containing 5% acetonitrile (v/v). Peptides
ere separated by isocratic elution for 5min followed by 20min of
inear gradient of 5–35% (v/v) acetonitrile in 0.1% phosphoric acid
t 1.5mL/min. Reaction products were detected by absorbance at
14nm. Peptide fragments were identiﬁed by elution position and
uantiﬁed by integration area.
.5.8. Kinetics parameters
The Michaelis–Menten constant (Km) was determined for puri-
ed ACE2 using variable concentration of Ang II as substrate
0.5–13M) at 37 ◦C, in 10mM Hepes buffer, pH 7.4 containing
25mM NaCl, 10M ZnCl2, 1M captopril and 50nM thior-
han. The product of hydrolysis of the Ang II by ACE2 was
nalyzed by reverse-phase HPLC. Km value was determined by
ineweaver–Burk equation and data were analyzed using the com-
uter softwareGraphPadPrismversion4.0 forWindows (Graphpad
oftware, USA).
.6. Immunoﬂuorescence
IMC were grown on sterilized coverslips, ﬁxed by incubation in
% paraformaldehyde in phosphate-buffer saline (PBS) and perme-
bilized in PBS with 0.2% gelatin. Fixed cells were incubated for
h with polyclonal antibody (C18 – Santa Cruz Biotechnologies,
SA) (1:10 dilution). The subsequent steps were carried out with
h incubation of FITC anti-goat (Sigma, USA) (1:100 dilution) and
′,6-diamidino-2-phenylindole (DAPI, Sigma, USA). Results were
nalyzed by confocal laser microscopy (Bio-Rad 1024-UV, USA).
. Results
.1. Puriﬁcation of ACE2 from IMC
The concentrated supernatant (100L), with ACE2 activity of
3.3nM/mL/min and speciﬁc activity of 7.41nM/mgwas applied to
n ion-exchange column equilibrated with 25mM Tris–HCl buffer,
H8,0, containing10MZnCl2.ACE2enzymatic activitywaseluted
s one peak with speciﬁc activity of 40.3nM/mg and was puriﬁed
.4 fold (Fig. 1 and Table 1).Abz-SPY(NO2) as substrate in buffer with NaCl concentrations ranging from 50 to
1500mM.
3.2. Puriﬁed ACE2 characterization
3.2.1. Optimum pH
Using the Abz-SPY(NO2) as substrate and buffers at pH ranging
from 4.0 to 9.0, the optimum pH value determined for the activity
of ACE2 enzyme was 7.5 (Fig. 2A).
3.2.2. Effects of Cl−, temperature and DX600 on ACE2 activity
The concentration of Cl− required for maximal activation of
ACE2 was 200mM (Fig. 2B) and the enzymatic stability was main-
tained between4 ◦C and37 ◦Cwhen the enzymewas pre-incubated
at different temperatures. ACE2 enzymatic activity was completely
inhibited by 1M, 10M and 100M DX600, described as a spe-
ciﬁc ACE2 inhibitor.
3.2.3. SDS-PAGE and Western blotting
The molecular mass determined by SDS-PAGE for puriﬁed ACE2
from IMC was around 60–70kDa. The homogeneity of ACE2 ana-
lyzed under dissociation conditions (Fig. 3A). The molecular mass
was conﬁrmed by Western blotting using anti-ACE2 antibody
(Fig. 3B).
3.2.4. Identiﬁcation of peptide bond in AII hydrolyzed by puriﬁed
ACE2preferred substrate Ang II. The puriﬁed ACE2 was able to hydrolyze
Ang II into Ang 1–7 (Fig. 4A and B).
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Table 1
Puriﬁcation of angiotensin-converting enzyme2 (ACE2) from immortalized mesangial cells using Abz-SPY(NO2) as substrate.
Step Volume (mL) Protein (mg/mL) Total Enzymatic activity (nM/min/mL) Speciﬁc activity (nM/mg) Puriﬁcation (X) Recovery (%)
Cell lysate 0.1 5.84 0.584 43.3 7.41 1 100
Resource Q 2.5 0.03 0.075 1.21 40.33 5.44 12.84
Fig. 3. (A) SDS-PAGE (7.5%) of reduced puriﬁed ACE2. Lane A: molecular mass
marker; lane B: puriﬁed material. Protein was stained with the Bio-Rad Silver
reagent (Bio-Rad, USA). (B) Western blotting of puriﬁed ACE2. Proteins were sepa-
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Fig. 4. Identiﬁcation of peptide bond in ANG II hydrolyzed by puriﬁed ACE2. The
RAS [1,2]. The pathophysiological role of this enzyme remains to be
determined, but its localization in the heart and kidney, and several
other tissues, suggests a crucial role for ACE2 in cardiovascular and
Table 2
Amino-terminal sequence of ACE2. Alignmentwith amino-terminal sequences from
human, mouse, horse, monkey and rat ACE2.
Description Sequence
ACE2 from IMC SWLLLS
ACE2 Equus caballus SWLLLS
ACE2 Mus musculus SWLLLSatedby SDS/PAGE (7.5% gel), transferred to anitrocellulosemembrane and revealed
ith anti-ACE2 antibody. Lane A: molecular mass marker; lanes B and C: puriﬁed
aterial.
.2.5. Amino-terminal sequence of puriﬁed ACE2
The N-terminal sequence of puriﬁed ACE2 determined by
dman degradation is shown in Table 2. A single sequence was
btained for the enzyme, and it is homologous with the N-terminal
equence of Homo sapiens, Mus musculus, Equus caballus, Macaca
ulatta, Cercopithius aethrops and Rattus norvegicus ACE2..2.6. Kinetics parameters
The Km of puriﬁed ACE2 was determined by constructing a
ineweaver–Burk plot (1/substrate versus 1/velocity) using Ang II
s substrate. The Km value was 2.87±0.76M (Fig. 5).conditions for reverse-phaseHPLC are given in Section 2. (A) Zero time of incubation
of ACE2 with ANG II. (B) After 24h of incubation of ACE2 with ANG II resulting in
ANG 1–7 generation.
3.3. Localization of ACE2 on IMC
To localize ACE2 in IMC these cells were grown to conﬂuence
and probed with a speciﬁc ACE2 antibody. Results of confocal
microscopy are shown in Fig. 6A–C. The nucleus of IMC was local-
ized with DAPI used as control (Fig. 6B). Under these conditions the
localization of ACE2 in IMC was mostly on the nuclei nevertheless
on the cytoplasm with low intensity (Fig. 6C).
4. Discussion
ACE2, a zincmetalloprotease,wasdescribed as anewmemberofACE2 Homo sapiens SWLLLS
ACE2 Macaca mulatta SWLLLS
ACE2 Cercopithecus aethiops SWLLLS
ACE2 Rattus norvegicus SWLLLS
D.S. Aragão et al. / International Journal of Biological Macromolecules 49 (2011) 79–84 83
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Fig. 6. Confocal ﬂuorescence microscopy of the ACE2 localization in mice IMC.
(A) Immortalized mesangial cells (DIC image). (B) Nuclei labeling with DAPI. (C)
Localization of ACE2 in immortalized mesangial cells using anti-ACE2 polyclonal
antibody. Original magniﬁcation 40×. Bar: 10m.ig. 5. Lineweaver–Burk plot for ACE2 activitu using ANG II as substrate. ANG II
oncentrations were expressed in M. Velocity was expressed as M/min.
enal disease [23]. In mice kidney, ACE2 expression was identiﬁed
n cortical tubules [24] and apical borders of the proximal convo-
uted tubules. Ye and collaborators described that ACE andACE2 are
trongly co-localized on the apical surface of the proximal tubules
nd are expressed in podocytes and in parietal epithelial cells of the
owman’s capsule. ACE2was also co-localizedwith smoothmuscle
ctin which may indicates its presence in MC. Tikellis and collab-
rators showed ACE2 mRNA in the kidney and localized to both
ubules and glomeruli. The moderated expression of ACE2 in the
lomeruli was conﬁrmed by immunohistochemistry [16].
In the present study, we demonstrated for the ﬁrst time the
resence of ACE2 in MC. The enzyme was puriﬁed 5.4 fold from
urine immortalized MC lysate, presenting a speciﬁc activity of
3.3nM/mg (Fig. 1 and Table 1). The puriﬁed enzyme presented
speciﬁc activity of 40.3, was identiﬁed as a single band on
DS-polyacrylamide gel (Fig. 3A) and by Western blotting using
speciﬁc antibody (Fig. 3B), conﬁrming a molecular mass around
0–70kDaand thehomogeneity of the enzyme.ACE2 from IMCwas
nhibited by DX600, a speciﬁc ACE2 inhibitor.
In the literature, ACE2 isoforms were described with molecular
ass rangingbetween70and130kDa.Donoghueandcollaborators
ere able to express a 90kDa recombinant ACE2 in the extracellu-
ar medium and cellular lysate using transfected CHO cells [1]. The
ame molecular mass was described for the enzymes identiﬁed in
at andmouse tissues [1,14]. However, ACE2 expressed inmammal
ells has amolecularmass of 120kDa reduced to 85kDa after enzy-
atic deglycosylation [2]. Other study also described ACE2 isoform
ith molecular masses ranging from 120 to 130kDa in rat kidney
16]. The authors suggest that these differences could be explained
y post-transductionalmodiﬁcations. AnACE2 presenting amolec-
larmass similar to the enzymedescribed in this study, 70kDa,was
uriﬁed from astrocyte cell culture, and was able to convert Ang
I into Ang 1–7, suggesting that this protein is a secreted form of
he enzyme [25]. Therefore, the lower molecular mass of puriﬁed
CE2 described by this study may be explained by deglycosylation
rocess or this enzyme could be a secreted ACE2 isoform.
The effect of Cl− on Abz-SPY(NO2) hydrolysis by ACE2 was
igher at a concentration of 200mM of NaCl (Fig. 2B) and an opti-
um pH of 7.5 (Fig. 2A). The enzyme activity was completely
nhibited by Cl− at concentrations ranging from 1M to 1.5M, dif-
ering from the data described by Yan collaborators that showed
aximal enzymatic activity at 1.5M NaCl at pH 7.5 for puriﬁed
CE2 fromtransfected SF21 cells [26] andalso fromVickers and col-
aborators that reported anoptimumactivity for recombinantACE2
rom SF9 cells in the presence of 1M NaCl at pH 6.5 [4]. Guy and
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[4 D.S. Aragão et al. / International Journal
ollaborators showed maximal activity at pH 7.0 in the presence of
00mMNaCl [27]. ACE2has conservedboth chloride ligands essen-
ial for its activity similar to ACE [28], suggesting that on other loci,
uch as renal tubular brush borders, is exposed to large ion ﬂuxes
nd may be regulated in a such manner. The result revealed that
he puriﬁed ACE2 from mouse mesangial cells had totally different
aCl dependent catalytic properties, but still has hydrolysis activ-
ty to Ang II, which means the puriﬁed product has ACE2 activity.
e believe the purity of this enzyme could be a reason for different
roperties revealed in this study.
The amino-terminal sequencing studies showed that puriﬁed
CE2 was similar to the sequence of H. sapiens, M. musculus, E.
aballus, M. mulatta, C. aethrops and R. norvegicus, supporting the
dentity of the enzyme (Table 2).
In this study ACE2 was localized mainly in the nuclei from
MC and poorly distributed on the cytoplasm (Fig. 6). Camargo de
ndrade and collaborators [13] showed the co-localization of ACE,
ng II and Ang 1–7 inside the cell nuclei of rat MC. The nuclear
resence of Ang II, the main substrate of ACE2 and the product of
ng II hydrolysis by this enzyme, Ang 1–7, can support our results.
oreover, it has already been demonstrated by immunoﬂuores-
ence staining that ACE2 is localized within glomerular structures
fmouse kidney, supporting the idea that the renal systemcontains
n endogenous system for angiotensin peptide production [15].
Rice and collaborators compared the kinetics of hydrolysis of
ng I and Ang II by ACE2, showing a high catalytic efﬁciency of Ang
I hydrolyzed by ACE2 when compared to Ang I hydrolysis by this
nzyme. The peptides angiotensin 1–9, Ang 1–7 and angiotensin
–5, were poorly hydrolyzed or not hydrolyzed at all by ACE2 [5].
In this study, the puriﬁed ACE2 was able to convert Ang II into
ng1–7 (Fig. 4A andB) (Km =2.87±0.76M,Fig. 5), suggesting that
CE2 prevents Ang II accumulation in the glomeruli, by regulating
he degradation of angiotensin peptides and supporting the con-
ept that ACE2 acts in a conter-regulatory manner to ACE and may
lay an important role to modulate the balance between vasocon-
trictors and vasodilators in the kidney.
Recently, Oudit and collaborators demonstrated a reduction
f mesangial matrix expansion when diabetic model mice were
reated with human recombinant ACE2. In the same study, the
reatment of primary rat MC culture with hrACE2 attenuated high
lucose and Ang II induced NADPH activity [29]. Taken together,
hese data support the hypothesis that the protective effect of ACE2
s mediated, at least in part, by a reduction in Ang II and an increase
n Ang 1–7.
Other study demonstrated an opposite effect of Ang 1–7 in dia-
etic kidney disease [30] and a possible stimulation of cell growth
athways in MC caused by this vasodilator peptide was suggested
y Dilauro and Burns [31].
The identiﬁcation of ACE2 in this study, clearly demonstrate
hat MC express ACE2, and that it could be responsible for Ang
–7 production, since this peptide was detected in the same cells
y immunoﬂuorescence analysis [13]. Although ACE2 may con-
ert Ang II to Ang 1–7 in MC, the relative contribution of ACE2
o total Ang 1–7 formation and function remains unclear. There
s agreement that angiotensins like Ang II and Ang 1–7 exerts sub-
tantial direct effects on the renalmicrovasculature and glomerular
esangium. The identiﬁcation and characterization of ACE2 in MC
ould be helpful to elucidate the mechanisms related to the regu-
ation of the levels of angiotensin peptides in these cells and the
[
[ogical Macromolecules 49 (2011) 79–84
production of ACE2 could prevent the local exposure to high levels
of Ang II, and therefore, exert a renoprotective effect.
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